Literature DB >> 10713806

Randomized controlled trial of once vs. twice daily gentamicin therapy in newborn.

R Solomon1, K A Kuruvilla, V Job, R Selvakumar, L Jeyaseelan, A S Kanagasabapathy, A K Jana.   

Abstract

OBJECTIVE: To compare the efficacy of once daily gentamicin administration to the conventional twice daily dosage schedule by estimation of serum gentamicin concentrations (SGC) in neonates.
DESIGN: Randomized controlled trial.
SETTING: Medical college hospital.
SUBJECTS: Seventy three neonates of gestational age>32 weeks at risk or with clinical features of sepsis.
METHODS: The subjects were divided into preterm and term groups. Babies in each of these groups were randomized to receive a single daily dose (4 mg/kg) or a twice daily dose (2.5 mg/kg) of injection gentamicin intravenously. Trough and peak SGC were estimated half an hour prior and one hour after the second dose. Statistical analysis was done using the equivalence method.
RESULTS: In preterm as well as term babies, the mean peak and trough gentamicin levels were comparable in the two regimens. There is statistically significant evidence to show that the effect of once daily and twice daily dosage is similar.
CONCLUSION: Once daily gentamicin administration is as effective as twice daily therapy and would be more cost effective.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10713806

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  4 in total

Review 1.  One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates.

Authors:  Shripada C Rao; Ravisha Srinivasjois; Kwi Moon
Journal:  Cochrane Database Syst Rev       Date:  2016-12-06

Review 2.  Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis.

Authors:  E Nestaas; H-J Bangstad; L Sandvik; K-O Wathne
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-04-27       Impact factor: 5.747

3.  Neonatal sepsis: a systematic review of core outcomes from randomised clinical trials.

Authors:  Cían J Henry; Gergana Semova; Ellen Barnes; Isabel Cotter; Tara Devers; Aisyah Rafaee; Andreea Slavescu; Niamh O Cathain; Danielle McCollum; Edna Roche; David Mockler; John Allen; Judith Meehan; Claus Klingenberg; Jos M Latour; Agnes van den Hoogen; Tobias Strunk; Eric Giannoni; Luregn J Schlapbach; Marina Degtyareva; Frans B Plötz; Willem P de Boode; Lars Naver; James L Wynn; Helmut Küster; Jan Janota; Fleur M Keij; Irwin K M Reiss; Joseph M Bliss; Richard Polin; Joyce M Koenig; Mark A Turner; Christopher Gale; Eleanor J Molloy
Journal:  Pediatr Res       Date:  2022-01-07       Impact factor: 3.953

Review 4.  Extended-interval dosing of gentamicin for treatment of neonatal sepsis in developed and developing countries.

Authors:  Gary L Darmstadt; Mary Miller-Bell; Maneesh Batra; Paul Law; Kiely Law
Journal:  J Health Popul Nutr       Date:  2008-06       Impact factor: 2.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.